CPI-613 is primarily used in the field of cancer research and treatment. It functions as a potent inhibitor of mitochondrial metabolism, specifically targeting enzymes involved in the tricarboxylic acid (TCA) cycle. By disrupting this crucial metabolic pathway, CPI-613 effectively starves cancer cells of the energy they need to proliferate, leading to their death. This mechanism makes it a promising candidate for combination therapies, where it is used alongside conventional chemotherapy or radiation to enhance their efficacy. Clinical trials have explored its use in treating various cancers, including pancreatic cancer, acute myeloid leukemia, and lymphoma, showing potential in improving patient outcomes. Additionally, its ability to selectively target cancer cells while sparing normal cells reduces the risk of severe side effects, making it a valuable tool in the development of more targeted and effective cancer treatments.